PRATIA MCM Kraków
- Address
- lock Available on a paid plan
Cardiovascular Diseases
PRATIA MCM Kraków conducts studies aimed at reducing cardiovascular disease events and improving vascular health.
- Hypertension management with novel peptide therapy
- Risk reduction in patients with established cardiovascular disease
- Evaluation of outcomes in high cardiovascular risk populations
These trials test new medicines and combination strategies to lower blood pressure. They also aim to prevent heart attacks and strokes, and enhance overall cardiovascular prognosis.
Hemic and Lymphatic Diseases
Research focuses on blood‑cancer disorders, seeking more effective options for patients with relapsed or refractory disease.
- Combination of BTK inhibitor and BCL2 inhibitor for chronic lymphocytic leukemia
- Targeted therapy for mantle‑cell lymphoma
- Novel agents for diffuse large B‑cell lymphoma
- Investigational treatments for follicular and marginal zone lymphoma
The goal is to improve response rates and extend survival by testing innovative drug regimens and personalized approaches.
Immune System Diseases
The centre evaluates therapies that modulate immune activity in kidney and skin conditions.
- Felzartamab to reduce proteinuria in IgA nephropathy
- Ruxolitinib cream for inflammatory skin disease prurigo nodularis
- Investigations of JAK inhibition in autoimmune disorders
These studies aim to lessen organ damage and skin inflammation by targeting key immune pathways.
Musculoskeletal Diseases
Clinical programs address joint inflammation and spinal disease, targeting pain relief and functional improvement.
- Filgotinib for active axial spondyloarthritis
- Izokibep to achieve ACR50 response in psoriatic arthritis
- Safety assessment of new biologics for musculoskeletal inflammation
The objective is to demonstrate that novel agents can control symptoms, halt disease progression, and improve quality of life.
Neoplasms
Oncologic research at the site spans solid tumors and blood cancers, testing cutting‑edge compounds.
- Adagrasib plus pembrolizumab for KRAS‑mutated non‑small cell lung cancer
- MK‑7648A in patients with high‑risk resected melanoma
- Brentuximab‑based regimen for relapsed diffuse large B‑cell lymphoma
- Combination therapies for advanced solid tumors
The trials seek to improve survival and disease‑free intervals by adding targeted agents to standard chemotherapy.
Respiratory Tract Diseases
Studies target malignant lung conditions, aiming to enhance treatment efficacy.
- KRAS G12C‑directed therapy for metastatic non‑small cell lung cancer
- Evaluation of novel agents in locally advanced lung cancer
- Combination immunotherapy approaches for respiratory malignancies
Research strives to increase overall survival and control tumor growth in patients with serious lung disease.
Skin and Connective Tissue Diseases
Dermatologic trials investigate both inflammatory skin disorders and cutaneous malignancies.
- Ruxolitinib cream for prurigo nodularis
- MK‑7648A in children and adults with skin cancer
- Safety profiling of topical agents for chronic skin inflammation
The purpose is to provide effective, well‑tolerated treatments that reduce lesions and improve skin health.
Circulatory and Respiratory Physiological Phenomena
The site also monitors physiological responses that underlie heart and lung function in trial participants.
- Assessment of cardiovascular biomarkers in hypertension studies
- Respiratory function testing in lung cancer trials
- Evaluation of hemodynamic changes during novel drug administration
Understanding these processes helps refine dosing, predict outcomes, and ensure patient safety across therapeutic areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 15 of 34 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
- 1Alnylam Pharmaceuticals Inc.1active
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in PRATIA MCM Kraków
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis | Acelyrin Inc. | Phase IV | Not Recruiting | Apr 2023 | Oct 2024 |
IMP list
lock Showing 1 of 34 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 3 | Unknown | 2025-06-12 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.